Pricing Log in Create free account
Friday 6 November 2026 Export GMAB’s income statement to Excel — free account

Genmab A/S Sponsored ADR

GMAB Healthcare Biotechnology

Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.

Revenue
+24.9%
EPS
−9.26%
Free cash flow
−7.69%

Quarter to June 2026, against a year earlier

53.58 0.84 +1.59%
Market cap
$31.5B
P/E
42.2×
Fwd P/E
47.3×
Dividend yield
—
F-score
4/9
Altman Z
2.78
Beneish M
−3.00
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Genmab A/S Sponsored ADR (GMAB) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, Genmab A/S Sponsored ADR (GMAB) trades at a EV/Sales of 8.8×. Over the past ten years it has ranged from 0.0× (September 2019) to 24.8× (December 2019); the current reading is higher than 49% of that period. That is in line with the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 6.1× 80.45%
FY2024 3.4× (52.41%)
FY2023 7.1× (41.40%)
FY2022 12.1× (28.41%)
FY2021 16.9× 8.91%
FY2020 15.6× 0.54%
FY2019 15.5× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period EV/Sales Change
Jun 2026 5.0× (6.18%)
Mar 2026 5.3× (13.40%)
Dec 2025 6.1× 40.30%
Sep 2025 4.3× 47.36%
27 more quarters

Against its own ten years

Low 0.0× High 24.8×
Ten-year median 9.0×
Current reading's percentile 44

EV/Sales against peers

Company EV/Sales
BNTX BioNTech SE Sponsored ADR compare 1.9×
INCY Incyte Corporation compare 3.4×
ALNY Alnylam Pharmaceuticals, Inc. compare 3.7×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 6.2×
GMAB Genmab A/S Sponsored ADR 8.8×
RPRX Royalty Pharma PLC compare 14.5×
INSM Insmed, Inc. compare 16.2×
RVMD Revolution Medicines, Inc. compare 185×
ROIV Roivant Sciences Ltd. compare 3,255×
Biotechnology industry median 9.0×
Healthcare sector median 3.6×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on GMAB